Northampton Electronic Collection of Theses and Research

High mobility group protein B1 is a predictor of poor survival in ovarian cancer

Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I. and Ramage, J. (2017) High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget. 8(60), pp. 101215-101223. 1949-2553.

[A][B][+][-]
9738:20115
[thumbnail of HMGB1 paper post review revisions - refs added_JMR_LM comments.docx]
HMGB1 paper post review revisions - refs added_JMR_LM comments.docx - Accepted Version
Restricted to Repository staff only
9738:30773
[thumbnail of Machado_etal_OT_2017_High_mobility_group_protein_B1_is_a_predictor_of_poor_survival_in_ovarian_cancer]
Machado_etal_OT_2017_High_mobility_group_protein_B1_is_a_predictor_of_poor_survival_in_ovarian_cancer
Machado_etal_OT_2017_High_mobility_group_protein_B1_is_a_predictor_of_poor_survival_in_ovarian_cancer.pdf - Published Version
Available under License Creative Commons Attribution.
Information
Abstract:
High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using tissue microarrays of primary ovarian cancers combined with a comprehensive database of clinicopathological variables, the expression of HMGB1 was assessed by immunohistochemistry in two independent cohorts (n=194 and n=360) using a monoclonal antibody specific for HMGB1. Kaplan-Meier analysis showed an association of HMGB1 expression with progression free survival in the primary cohort (p=0.023). In the validation cohort, expression was associated with overall survival (p=0.002). Low expression of HMGB1 was protective and in a multivariate model HMGB1 expression was shown to be an independent predictor of poor survival in ovarian cancer (p=0.006). The role of HMGB1 in cancer is complex. As high levels of HMGB1 expression are likely to render ovarian cancer cells resistant to chemotherapy, therapies targeting the HMGB1 axis may be appropriate in the treatment of ovarian cancer patients.
Uncontrolled Keywords:
/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Creators:
Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I. and Ramage, J.
Faculties, Divisions and Institutes:
Faculties > Faculty of Health & Society > Sports, Exercise & Life Sciences
Research Centres > Centre for Health Sciences and Services
Research Centres > Centre for Physical Activity and Life Sciences
Date:
24 November 2017
Date Type:
Publication
Page Range:
pp. 101215-101223
Journal or Publication Title:
Oncotarget
Volume:
8
Number:
60
Number of Pages:
9
Language:
English
DOI:
10.18632/oncotarget.20538
ISSN:
1949-2553
Status:
Published / Disseminated
Refereed:
Yes
Related URLs:
Edit Item